In this issue:
Multiple myeloma in the time of COVID-19
Melflufen plus dexamethasone in RRMM
MOR202, a novel anti-CD38 monoclonal antibody, in patients with RRMM
Venous thromboembolism risk with lenalidomide-based regimens
Early intervention with lenalidomide delays disease progression in smoldering MM
Pain management in MM
Comparing MM regimens: efficacy, safety and cost considerations
GRIFFIN shows an advantage to the addition of DARA to RVd for NDMM
Outcomes of oligosecretory and non-secretor MM
14-3-3ε expression predicts sensitivity to proteasome inhibitors
Please login below to download this issue (PDF)